In contrast to the predicted adverse consequences of DMRs in patients with PAH and TET2 mutations, none of the hypermethylated DMRs that were unique to non‐TET2 PAH predicted pathologic changes in gene function. The gene discussed is TET2; the disease is pulmonary arterial hypertension.